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SELECTION OF THE MONTH 
Big Title: Obese adolescents at high risk of severe liver disease in later life 
 
Small title Cirrhosis and Liver Failure: Moderate hypothermia in ALF 
 
ACUTE LIVER FAILURE (ALF) 
Autophagy cleans acetaminophen protein adducts, moderate hypothermia and 
intracranial hypertension in ALF 
Acetaminophen (APAP)-induced liver injury is the most common cause of acute liver 
failure worldwide. APAP metabolism gives rise to metabolites NAPQI, which bind to 
cellular and mitochondrial proteins to form APAP protein adducts (APAP-AD). 
Mitochondrial APAP-AD trigger mitochondrial damage which may result in necrotic cell 
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death and subsequent liver injury. Little is known on how hepatocytes can remove 
APAP-AD. Using elegant approaches (in vivo mouse model and in vitro experiments), 
Ni et al. show that APAP-AD are removed through selective autophagy. The autophagy 
receptor protein p62 is recruited to APAP-AD, which could facilitate APAP-AD 
transition to the detergent insoluble form and allow their recognition and enwrappment 
by autophagosomes. Pharmacological induction of autophagy (Torin 1) or inhibition of 
autophagy (Leu or CQ) improves or impairs autophagic removal of APAP-AD and 
results in protection or exacerbation of APAP-induced necrosis and liver injury, 
respectively. They suggest that pharmacological induction of autophagy may be a 
novel approach for treating APAP-induced liver injury.   
In patients with ALF, the occurrence of encephalopathy defines the condition and is 
associated with increased risk of death. Cerebral edema is a characteristic feature of 
encephalopathy in ALF patients and about 15% patients die from the effects of 
increased intracranial pressure (ICP). When the increase in ICP is uncontrolled with 
medical management, application of moderate hypothermia is effective at controlling 
ICP. Bernal et al. performed the first randomized and controlled clinical trial of 
moderate hypothermia in ALF patients to determine whether it could prevent the 
development of increased ICP. The study revealed that moderate hypothermia 
did not confer benefit in prevention of intracranial hypertension or in overall 
survival compared with standard of care. The data do not support the use of 
moderate hypothermia in a prophylactic mode. 
 
FIBROSIS 
A novel antifibrotic approach 
Interleukin (IL)-15 binds with high affinity to IL-15 receptor subunit alpha (IL-15RA) to 
activate Janus kinase/signal transducers and activators of transcription (JAK/STAT) 
signaling pathways. IL-15 (and IL-2 as well) stimulates the proliferation of T cells; 
induces the generation of cytotoxic T lymphocytes (CTLs); facilitates the proliferation 
of, and the synthesis of immunoglobulin, by B cells; and induces the generation and 
persistence of natural killer (NK) cells. IL-15 is important for the maintenance of long-
lasting, high-avidity T-cell responses to invading pathogens, and it achieves this by 
supporting the survival of CD8+ memory T cells. IL-15RA is expressed in immune cells 
and hepatic resident cells. Jiao et al. hypothesized that IL-15RA engagement by its 
agonist may result in antifibrotic actions. They show that in mice IL-15RA activation 
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results in anti-fibrotic effects through direct effects on hepatic stellate cells (HSC), 
independently of any action on natural killer homeostasis. They suggest that future 
studies should explore the anti-fibrotic potential of enhancing IL-15 signaling in 
hepatic stellate cells. 
 
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) 
Overweight in late adolescence and severe liver disease in adults, Sitagliptin 
therapy in pre-diabetic or diabetic patients with NAFLD. 
The increased prevalence of overweight has been suggested to contribute to the 
worldwide increase in liver diseases. Hagström et al. analyzed a cohort study using 
data from 45,000 young men in Sweden 1970 and collected from the participants any 
diagnosis of severe liver disease until 2009. The authors found that overweight was 
strongly associated with an increased risk of development of severe liver 
disease. This important epidemiological data suggests that early interventions in 
young overweight individuals could prevent the development of severe liver disease. 
Uncontrolled studies show sitagliptin, an oral DPP-4 inhibitor, may decrease ALT and 
improve histology in patients with NAFLD. In this issue, Cui et al. performed a placebo-
controlled trail assessing the efficacy of sitagliptin in pre-diabetic and diabetic patients 
with NAFLD. Fifty NAFLD were randomized to sitagliptin orally 100 mg/day or placebo 
for 24 weeks. Sitagliptin was not significantly better than placebo in reducing 
liver fat (measured by MRI-PDFF) nor decreased ALT, HOMA and liver stiffness. 
The study clearly demonstrated that Sitagliptin was safe but not better than placebo in 
patients with NAFLD. 
 
GENETIC LIVER DISEASES 
Respiratory mitochondrial complex III regulates liver adaptation to fasting 
The respiratory complex III, which has 11 structural subunits and requires several 
assembly factors, plays an important role in liver homeostasis. Kremer et al. report the 
case of a child with complex III defect and acute liver dysfunction with lactic acidosis, 
hypoglycemia, and hyperammonemia. Homozygous, truncating, mutations were found 
in LYRM7 and MTO1. The protein encoded by LYRM7 is a nuclear-encoded 
mitochondrial matrix protein that stabilizes Rieske Fe-S protein (known as UQCRFS1) 
and chaperones it to the inner mitochondrial membrane complex III (CIII, which is the 
main enzyme complex in the mitochondrial respiratory chain). MTO1 encodes a 
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mitochondrial protein thought to be involved in mitochondrial tRNA modification. 
Comparison of the patient's clinical history to previously reported patients with complex 
III defect due to nuclear DNA mutations showed striking similarities. This intriguing 
study demonstrates that profound complex III defect in liver impedes liver 
adaptation to prolonged fasting leading to severe lactic acidosis, hypoglycemia. 
 
HEPATITIS C VIRUS (HCV) INFECTION 
HCV screening strategies in the US, spontaneous HCV clearance in chronic 
infection, viral escape by HCV core sequence-specific modulation of NK cell 
function 
As curing chronic hepatitis C virus (HCV) infection can be now effectively achieved in 
nearly all patients, strategies to bring patients being unaware of their infection into 
medical care is of upmost importance in order to reduce the future population-based 
HCV-related disease burden. To achieve this goal, the Centers for Disease Control 
and the United States Preventive Services Task Force recommended universal one-
time anti-HCV testing for Americans born 1945-1965, as more than 70% of all HCV 
infections in the U.S. belong to this birth cohort. Sarkar et al. studied patterns and 
predictors of HCV testing across the U.S. within this birth cohort utilizing data from the 
national corporate data warehouse of the U.S. Veterans Administration health system. 
From the more than 4.2 Million birth cohort veterans being in medical care only 51% 
had HCV testing with significant variations in testing among the different centers 
(Range: 7-83%). Hence, further improvement in HCV screening is needed and the 
current work may provide an important basis in order to optimize future national 
HCV screening strategies. 
Spontaneous clearance of chronic HCV infection is believed to occur only exceptionally 
but valid estimates about its true incidence are missing. To elucidate the true 
spontaneous clearance rate in chronically infected patients, Bulteel et al. used 
retrospective data obtained on HCV testing between 1994 and 2013 in the West of 
Scotland and defined spontaneous HCV clearance as ≥ 2 sequential samples positive 
for HCV RNA ≥ 6 months apart followed by ≥ 1 negative test. The incidence rate of 
spontaneous HCV clearance was surprisingly high with 0.36/100 person-years follow-
up among 10,318 untreated patients with chronic HCV infection, and female gender, 
younger age at infection, lower HCV RNA load and co-infection with hepatitis B virus 
were positively associated with this event. This important study highlights that 
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spontaneous clearance may occur in certain subgroups even after a prolonged 
duration of chronic infection more frequently as expected. Further work is required 
to identify the mechanisms underlying spontaneous clearance. 
Viral host interactions involving regulators of the innate and adaptive immune system 
play an important role in viral escape mechanisms, and in this process the level of 
interaction is also driven by both, host but also viral genetic variants. The study by 
Lunemann et al. provides new insights how HCV type specific viral peptides influence 
natural killer (NK) cell function by targeting the killer cell immunoglobulin like receptors 
(KIRs), which interact mainly with HLA class I molecules on the surfaces of other cells. 
The authors show that the HCV core-derived viral epitope YIPLVGAPL increases 
binding of the inhibitory KIR2DL3-encoded protein to the respective HLA 
C*03:04/peptide complex, leading to a significant inhibition of KIR2DL3+ NK cell 
function. They provide first evidence of a novel pathway by which HCV might be 
able to evade NK cell-mediated recognition. 
 
HEPATOCELLULAR CARCINOMA (HCC) 
Biomarkers for HCC, histone deacetylase inhibitors for HCC 
Two translational studies published in this issue of the Journal provide new 
perspectives in the development of biomarkers in patients with HCC. Ogle et al. 
investigated blood in patients with HCC and controls, using an imaging flow cytometry 
method (with immunofluorescence of cytokeratin, EpCAM, AFP, glypican-3 and DNA-
PK) together with analysis of size, morphology and DNA content. They show that in 
patients with HCC, the use of multiple parameters enhances detection sensitivity 
of circulating tumor cells, revealing biological associations and predictive 
biomarker potential that may guide future research. Zhu et al. investigated whether 
baseline plasma and archival tissue specimens collected from patients enrolled in the 
EVOLVE-1 trial (a randomized phase 3 study of everolimus in HCC) were associated 
with prognosis, etiology or ethnicity. They find that the higher plasma levels of two 
proteins, vascular endothelial growth factor and soluble vascular endothelial growth 
factor receptor 1 (both known to be involved in the angiogenesis process), the poorer 
the prognosis. Moreover, their results reveal potential differences in cMet 
(hepatocyte growth factor receptor) and mTOR (mammalian target of rapamycin) 
pathway activation between Asian and non-Asian patients, suggesting that 
these differences should be considered in future clinical trials. 
6 
 
Bitzer et al. enrolled patients with HCC and radiologically confirmed progression on 
sorafenib in a phase I/II trial. This trial aimed to investigate safety, pharmacokinetics 
(PK) and potential biomarkers of the histone deacetylase (HDAC) inhibitor resminostat 
and a combination therapy with resminostat and sorafenib. They show that the 
combination of sorafenib and resminostat is safe and may have early efficacy. 
Sorafenib does not alter the PK profile of resminostat or its HDAC inhibitory activity in 
vivo. Moreover, they find that baseline levels of zinc finger protein 64 levels in blood 
cells may be a predictor of overall survival in HCC. 
